Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.36 |
| ▸ | DRD3 | P35462 | 8/20 | 0.36 |
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 4/20 | 0.35 |
| ▸ | DRD1 | P21728 | 3/20 | 0.35 |
| ▸ | DRD5 | P21918 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875077 | 0.97 | DRD2 (0.39) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL4871971 | 0.83 | HTR1A (0.55) | DRD2HTR1A | |
| SCHEMBL4875781 | 0.80 | HTR1A (0.53) | DRD2HTR1A | |
| SCHEMBL4876727 | 0.76 | DRD2 (0.40) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL4871708 | 0.74 | MEN1 (0.38) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL4871786 | 0.73 | KMT2A (0.50) | DRD2DRD3ALDH1A1 | |
| SCHEMBL4871876 | 0.72 | DRD2 (0.39) | DRD2DRD3HTR2ADRD4DRD1 | |
| SCHEMBL4872373 | 0.71 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL5118022 | 0.71 | GOT1 (0.46) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL4874631 | 0.71 | DRD2 (0.42) | DRD2DRD3HTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393845-B2 | Heteroaryl derivates, their preparation and use | H. LUNDBECK A/S (DK) | 2008-07-01 | — | — | US | claimed |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | claimed |
| EP-1399438-B1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2005-12-07 | — | — | EP | claimed |
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2004-12-09 | — | — | US | claimed |
| EP-1399438-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2004-03-24 | — | — | EP | claimed |
| WO-2003002556-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2003-01-09 | — | — | WO | claimed |
| US-7393845-B2 | Heteroaryl derivates, their preparation and use | H. LUNDBECK A/S (DK) | 2008-07-01 | — | — | US | disclosed |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | disclosed |
| EP-1399438-B1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2005-12-07 | — | — | EP | disclosed |
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2004-12-09 | — | — | US | disclosed |
| EP-1399438-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002556-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | GRIN2C, GRIN2B, HTR1A | DRD2 20/4885DRD3 27/4885HTR2A 41/4885 |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | GRIN2C, GRIN2B, HTR2C | DRD2 23/4885DRD3 29/4885HTR2A 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.